Physician profile
Bradley S Eilerman
NPI 1841389822
$1,279,958.61
in general payments reported to CMS, 2019-2025
80 companies · $275K in 2025
The $275K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $188K · 2020: $147K · 2021: $125K · 2022: $198K · 2023: $116K · 2024: $230K · 2025: $275K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $441K · Travel and Lodging: $65K · Honoraria: $39K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $36K · Consulting Fee: $22K · Food and Beverage: $20K · Education: $72.27 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $440,727.78 |
| Travel and Lodging | $64,979.39 |
| Honoraria | $38,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,851.50 |
| Consulting Fee | $21,816.75 |
| Food and Beverage | $19,799.78 |
| Education | $72.27 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $393,402.70 | 2019-2025 | Korlym |
| Novo Nordisk INC | $320,009.49 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $287,651.32 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $64,517.95 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $45,888.08 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $36,771.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,752.01 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $26,016.25 | 2019-2025 | |
| Abbvie INC. | $9,636.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $7,436.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $7,336.22 | 2019 | |
| Recordati_rare_diseases_inc. | $7,245.17 | 2022-2025 | Isturisa, Osilodrostat |
| Novo Nordisk As | $5,935.57 | 2025 | |
| Shire North American Group INC | $5,635.21 | 2019 | |
| Abbott Laboratories | $5,088.37 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $4,212.00 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Eli Lilly and Company | $2,600.00 | 2020-2025 | |
| Clarus Therapeutics INC. | $2,464.12 | 2021 | |
| Biomarin Pharmaceutical INC. | $2,457.00 | 2022 | |
| Medtronic Minimed, INC. | $2,399.11 | 2019-2020 | |
| Zealand Pharma US, INC. | $1,634.71 | 2021-2022 | |
| Amgen INC. | $1,035.09 | 2019-2025 | Repatha, Tepezza, Evenity |
| Medtronic, INC. | $873.23 | 2021-2025 | Minimed 780g |
| Ibsa Pharma INC. | $828.82 | 2019-2024 | Tirosint, Tirosint, Licart |
| Insulet Corporation | $536.62 | 2019-2025 | Omnipod |
| Mannkind Corporation | $476.89 | 2019-2023 | Afrezza |
| Amarin Pharma, INC. | $440.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $440.04 | 2022-2025 | |
| Antares Pharma, INC. | $332.57 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Alexion Pharmaceuticals, INC. | $318.77 | 2021-2025 | Strensiq |
| Radius Health, INC. | $288.24 | 2019-2025 | Tymlos |
| Exact Sciences Corporation | $270.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lifescan, INC. | $246.61 | 2019-2023 | |
| Pfizer INC. | $226.68 | 2019-2025 | |
| Beta Bionics, INC. | $189.78 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Becton, Dickinson and Company | $162.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $138.56 | 2021-2025 | Evkeeza |
| Neurocrine Biosciences, INC. | $135.33 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $128.24 | 2023-2025 | Yorvipath, Skytrofa |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2020 | |
| Astellas Pharma US INC | $124.96 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.09 | 2019-2023 | Cycloset |
| Esperion Therapeutics, INC. | $104.47 | 2021-2025 | Nexletol |
| Horizon Therapeutics Plc | $95.72 | 2020-2023 | Tepezza |
| Eisai INC. | $94.18 | 2019 | |
| Amryt Pharma Holdings Ltd | $82.07 | 2020-2023 | Mycapssa, Juxtapid |
| Rhythm Pharmaceuticals, INC. | $75.62 | 2022-2025 | Imcivree, Imcivree |
| Cequr Corporation | $73.56 | 2024-2025 | Cequr Simplicity |
| Valeritas, INC. | $72.84 | 2019 | |
| Tandem Diabetes Care, INC. | $70.62 | 2019-2022 | |
| Tolmar, INC. | $60.49 | 2023-2025 | Jatenzo |
| Endo Pharmaceuticals INC. | $55.61 | 2019-2022 | |
| Kyowa Kirin, INC. | $54.07 | 2023-2025 | Crysvita |
| Sequel Med Tech, LLC | $47.18 | 2024-2025 | Twiist |
| Amneal Pharmaceuticals LLC | $46.74 | 2019-2025 | Unithroid |
| Averitas Pharma INC. | $45.48 | 2025 | Qutenza |
| Eusa Pharma (US) LLC | $39.69 | 2022 | |
| Grifols USA, LLC | $37.68 | 2023 | Prolastin-C Liquid |
| Verity Pharmaceuticals INC. | $36.31 | 2024-2025 | Tlando |
| Halozyme INC | $29.99 | 2023 | |
| Vivus LLC | $28.51 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $28.14 | 2019 | |
| Embecta Corp. | $25.03 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Almatica Pharma LLC | $25.00 | 2025 | Teriparatide |
| E.R. Squibb & Sons, L.L.C. | $19.52 | 2023 | Eliquis |
| Avvisto Therapeutics, LLC | $18.60 | 2025 | Cycloset |
| Nestle Healthcare Nutrition INC. | $17.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.55 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.17 | 2019 | |
| Chiesi USA, INC. | $16.69 | 2025 | Myalept, Juxtapid |
| Soleno Therapeutics, INC. | $14.96 | 2025 | Vykat Xr |
| Roche Diabetes Care, INC. | $14.88 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.74 | 2022 | |
| Currax Pharmaceuticals LLC | $13.14 | 2020 | |
| Daiichi Sankyo INC. | $11.45 | 2020 | |
| Ucb, INC. | $10.91 | 2019 | |
| Aytu Biopharma, INC. | $10.85 | 2019 | |
| Kvk-Tech, INC. | $4.37 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,677.56 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Eilerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.